Investor Relations Home
Download Documentation 2016 Guidance Worksheet
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation Update on ABP-700
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation ABP-700 & MDCO-216 Conference Call Presentation
Corporate Profile
The Medicines Company provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.
Stock Quote
MDCO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$50.69
Change (%) Stock is Up 0.70 (1.40%)
Volume1,172,089
Data as of 03/24/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
03/17/17The Medicines Company and Alnylam Pharmaceuticals Report Positive Final Results from ORION-1 Phase II Study of Inclisiran
—Inclisiran demonstrated significant and sustained reductions in LDL-C and high standards of safety and tolerability— —Optimal starting dose regimen (300 mg injection administered on Day-1 and Day-90) lowered LDL-C by average of 52.6% (64 mg/dL) and up to 81% (122 mg/dL) at Day-180, and by time-adjusted mean of >50% (63 mg/dL) for the six-month period from Day-90 through Day-270; every patient displayed significant response and mean LDL-C redu... 
Printer Friendly Version
03/14/17The Medicines Company to Webcast Presentation of ORION-1 Phase II Study of Inclisiran at ACC.17
Late-breaking session featuring data from ORION-1 study to be webcast simultaneously with presentation at 1:30 p.m. on March 17, 2017 New Time for Conference Call – Previously-scheduled conference call/webcast to review data from ORION-1 moved to 4:30 p.m. on March 17, 2017 PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 14, 2017-- The Medicines Company (NASDAQ: MDCO) today announced that it will webcast, over the internet simultaneousl... 
Printer Friendly Version
03/06/17The Medicines Company to Host Conference Call and Webcast at Upcoming American College of Cardiology’s 66th Annual Scientific Sessions
– Late-breaking data from ORION-1 Phase II study of inclisiran (PCSK9si) will be reviewed by the Company and members of its distinguished advisory board – PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 6, 2017-- The Medicines Company (NASDAQ:MDCO) will host a conference call and webcast on Friday, March 17, 2017, at 3:30 p.m., Eastern Time, to review data from the ORION-1 Phase II study of inclisiran, the Company’s PCSK9 synthesis inhibitor. D... 
Printer Friendly Version
02/28/17The Medicines Company Reports Fourth-Quarter and Full-Year 2016 Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 28, 2017-- The Medicines Company (NASDAQ:MDCO) today announced its financial results for the fourth-quarter and full-year ended December 31, 2016. “Driven by strong execution against our strategic priorities, 2016 was a transformative year for the Company,” said Clive Meanwell, M.D., Ph.D., Chief Executive Officer of The Medicines Company. “We announced positive top-line results from the ORION-1 Phas... 
Printer Friendly Version
Upcoming Events
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.